Anaphylactic Reaction to Pemetrexed: A Case Report

Pemetrexed is approved to treat non-small cell lung cancer and has an overall favorable toxicity profile. We describe a 58-year-old man who developped an anaphylactic shock within few minutes from the beginning of pemetrexed perfusion. Pemetrexed was discontinued and the patient’s symptoms graduall...

Full description

Bibliographic Details
Main Authors: Heloise Capelle, Joelle Birnbaum, Pascale Tomasini, Céline Tummino, Marion Gouitaa, Nathalie Ausias, Denis Charpin, Fabrice Barlesi, Marc Montana
Format: Article
Language:English
Published: Canadian Society for Pharmaceutical Sciences 2014-05-01
Series:Journal of Pharmacy & Pharmaceutical Sciences
Online Access:https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/21453

Similar Items